CART-19 Immunotherapy in Mantle Cell Lymphoma

Summary

Patients receive anti-CD19-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells over a period of 4 or 5 consecutive days in an escalating dose. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 years.

Timeline

Start

2014-03

Primary completion

2018-12

Completion

2019-12

Drugs

Indications